P670: ABSENCE OF BTK, BCL2, AND PLCG2 MUTATIONS IN RELAPSING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER FIRST-LINE TREATMENT WITH FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V)

• L. J. Croner,
• J. N. Allan,
• N. Jain,
• J. F. Seymour,
• K. Eckert,
• L. W. K. Cheung,
• E. Szafer-Glusman

Affiliations

L. J. Croner

1 AbbVie, North Chicago, IL

J. N. Allan

3 Weill Cornell Medicine, New York, NY

N. Jain

4 MD Anderson Cancer Center, Houston, TX, United States of America

J. F. Seymour

5 Peter MacCallum Cancer Center & Royal Melbourne Hospital, Melbourne, VIC, Australia

K. Eckert

2 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA

L. W. K. Cheung

1 AbbVie, North Chicago, IL

E. Szafer-Glusman

1 AbbVie, North Chicago, IL